Free Trial
TSE:CRDL

Cardiol Therapeutics (CRDL) Stock Price, News & Analysis

Cardiol Therapeutics logo
C$1.60 +0.11 (+7.38%)
As of 05/27/2025 04:00 PM Eastern

About Cardiol Therapeutics Stock (TSE:CRDL)

Key Stats

Today's Range
C$1.49
C$1.60
50-Day Range
C$1.19
C$1.63
52-Week Range
C$1.09
C$4.26
Volume
80,450 shs
Average Volume
73,576 shs
Market Capitalization
C$132.77 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada.

Receive CRDL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cardiol Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

CRDL Stock News Headlines

Stocks in play: ardiol Therapeutics Inc.
Elon’s 2025 Silver Crisis (What It Means for You)
Elon Musk is back in the spotlight—this time for fueling a global scramble for silver. Tesla's relentless production of electric vehicles and solar technology is driving demand for the precious metal to unprecedented levels. Silver—critical for EV batteries, solar panels, and advanced electronics—is now at the center of a supply crisis.
Cardiol Therapeutics added to PRISM Emerging Biotech Index
Cardiol Therapeutics Expands Trials for Heart Treatment
See More Headlines

CRDL Stock Analysis - Frequently Asked Questions

Cardiol Therapeutics' stock was trading at C$1.85 at the start of the year. Since then, CRDL shares have decreased by 13.5% and is now trading at C$1.60.
View the best growth stocks for 2025 here
.

Shares of CRDL stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.

Based on aggregate information from My MarketBeat watchlists, some other companies that Cardiol Therapeutics investors own include Cardiol Therapeutics (CRTPF), Rolls-Royce Holdings plc (RR.L), Very Good Food (VRYYF), Gilead Sciences (GILD), Impel Pharmaceuticals (IMPL), Luminar Technologies (LAZR) and Meta Platforms (META).

Industry, Sector and Symbol

Stock Exchange
TSE
Sector
Medical
Industry
Drug Manufacturers - Specialty & Generic
Sub-Industry
Pharmaceutical Products
Current Symbol
TSE:CRDL
CIK
N/A
Fax
N/A
Employees
20
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-C$42.93 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Cash Flow
C$1.63 per share
Price / Cash Flow
0.98
Book Value
C$0.15 per share
Price / Book
10.71

Miscellaneous

Free Float
N/A
Market Cap
C$132.77 million
Optionable
Not Optionable
Beta
0.70
Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

This page (TSE:CRDL) was last updated on 5/28/2025 by MarketBeat.com Staff
From Our Partners